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The MALDI Biotyper Selective Testing of Antibiotic Resistance–β-Lactamase (MBT 33 
STAR-BL) assay, which analyzes bacterial induced hydrolysis of cefotaxime using 34 
MALDI-TOF MS, correctly identified 100.0% of extended-spectrum β-lactamase 35 
(ESBL)-producing Enterobacteriaceae as positive and 94.7% of non-ESBL producers 36 
as negative in 80 strains tested. 37 
 38 





Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae represent a 41 
significant public health concern. A previous study from Japan reported that ESBL-42 
producing Escherichia coli and Klebsiella pneumoniae are spreading, accounting for 43 
23.0% of E. coli and 10.7% of K. pneumoniae infections in 2014-2015 (Takesue et al., 44 
2017). 45 
We recently reported the reliable performance of the MALDI Biotyper Selective 46 
Testing of Antibiotic Resistance–β-Lactamase (MBT STAR-BL) assay, which analyzes 47 
bacterial induced hydrolysis of β-lactam antibiotics using matrix-assisted laser 48 
desorption ionization–time-of-flight mass spectrometry (MALDI-TOF MS), for 49 
detecting IMP metallo-β-lactamase (MBL) activity in Enterobacteriaceae (Kawamoto et 50 
al., 2018). In the present study, we also investigated the utility of the MBT STAR-BL 51 
assay for the detection of ESBL activity in Enterobacteriaceae. 52 
We used Enterobacteriaceae (E. coli and K. pneumoniae) clinically isolated at the 53 
Nagasaki University Hospital between January 2011 and May 2016. MICs were 54 
determined using a BD Phoenix Automated Microbiology System (BD Diagnostics). 55 
ESBL production was also detected using the BD Phoenix system (Leverstein-van Hall 56 




PCR. PCR amplification of ESBL genes (variants of CTX-M–group 1, including CTX-58 
M-1, CTX-M-3, and CTX-M-15; variants of CTX-M–group 2, including CTX-M-2; 59 
variants of CTX-M–group 9, including CTX-M-9 and CTX-M-14; TEM variants, 60 
including TEM-1 and TEM-2; and SHV variants, including SHV-1) was performed 61 
using previously described primers (Dallenne et al., 2010) under the following 62 
conditions: 10 min at 95°C, 30 cycles consisting of 40 s at 95°C, 40 s at 60°C, 1 min at 63 
72°C, and 7 min at 72°C for the final extension for ESBL genes, as described previously 64 
(Higashino et al., 2017). Analysis of cefotaxime hydrolysis using the MBT STAR-BL 65 
assay (including calibration) was performed according to the manufacturer’s 66 
instructions, as described previously (Kawamoto et al., 2018). Three to five individual 67 
bacterial colonies were randomly collected using a 1-µL inoculation loop, suspended in 68 
50 μL of solution (10 mM NH4CO3, 10 μg/mL ZnCl2 [pH 8]) containing 0.5 mg/mL of 69 
cefotaxime, and incubated at 37°C for 2 h according to the manufacturer’s instructions. 70 
Signal peak intensity was used to calculate the logRQ value (a measure of 71 
hydrolysis efficiency), which was the logarithm of the ratio of the summed intensity of 72 
the hydrolyzed form (molecular peaks of [Mhydrolyzed/deacetyl + H]+ at 414 m/z and 73 
[Mhydrolyzed/decarboxylated/deacetyl + H]+ at 370 m/z) to the summed intensity of the non-74 




m/z and [M + 2Na]+ at 500 m/z, and [Mdeacetyl + H]+ at 396 m/z). Higher logRQ values 76 
indicated a higher degree of antibiotic hydrolysis (Kawamoto et al., 2018; Oviano and 77 
Bou, 2017). The 95% confidence intervals (CIs) for sensitivity and specificity were 78 
calculated using R statistical software (https://cran.ism.ac.jp/) (Kosai et al., 2017; 79 
Yamakawa et al., 2018). Dot plots were generated using EZR 80 
(http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html). 81 
A total of 80 strains (42 E. coli and 38 K. pneumoniae) were used for the 82 
cefotaxime hydrolysis assay, and the characteristics of these strains are presented in 83 
Table 1. Of the 80 strains, 42 (22 E. coli and 20 K. pneumoniae) harbored ESBL genes 84 
that were not detected in the remaining 38 strains. The most prevalent ESBL genotype 85 
was the CTX-M type, and 23 strains harbored multiple ESBL genes. The results of 86 
ESBL production assays using the BD Phoenix system were consistent with the 87 
presence or absence of ESBL genes in all 80 strains. ESBL producers and non-88 
producers were defined as strains positive for both ESBL genes and ESBL production 89 
and as strains negative for both ESBL genes and ESBL production, respectively. 90 
Representative spectra of the cefotaxime hydrolysis assay analyzed using the MBT 91 
STAR-BL assay are presented in Figure 1. The distribution of normalized logRQ values 92 




identified as positive. With respect to the 38 non-ESBL producers, 36 were correctly 94 
identified as negative, whereas 1 strain was indeterminate and 1 strain was identified as 95 
positive. The sensitivity and specificity of the cefotaxime hydrolysis assay for the 96 
detection of ESBL activity were 100.0% (95% CI, 91.6–100.0) and 94.7% (95% CI, 97 
82.3–99.4), respectively. 98 
Our results indicate that the MBT STAR-BL assay exhibits excellent performance, 99 
with high sensitivity and specificity. The results of previous studies using similar 100 
detection systems were consistent with our present results, suggesting that the assay is 101 
reliable for the detection of ESBL-producing strains (Oviano et al., 2014; Oviano et al., 102 
2017). The resistance of the two non-ESBL producers identified as indeterminate or 103 
positive by the cefotaxime hydrolysis assay could be associated with plasmid-mediated 104 
inducible β-lactamases not evaluated in this study (Empel et al., 2010; Jacoby, 2009; 105 
Yong et al., 2005). 106 
There are some limitations to the present study. First, we examined only cefotaxime 107 
under a single condition (concentration, 0.5 mg/mL; incubation time, 2 h). However, it 108 
should be recognized that differences in bacterial concentration, antibiotic, drug 109 
concentration, and incubation time could affect the results of this assay (Mirande et al., 110 




institution, and CTX-M was the major genotype of these strains. Because epidemiologic 112 
differences could have affected the results, further studies using strains isolated in other 113 
regions and including a variety of genotypes will be necessary in order to confirm the 114 
assay performance. 115 
In conclusion, this study demonstrated that the MBT STAR-BL assay enables 116 
detection of ESBL-producing Enterobacteriaceae with high accuracy, thereby making it 117 
suitable for screening ESBL producers. 118 
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Figure legends 189 
Figure 1. Representative spectra of the cefotaxime hydrolysis assay analyzed using the 190 
MBT STAR-BL assay. Non-ESBL producers exhibited peaks at 456, 478, and 396 m/z, 191 
corresponding to the non-hydrolyzed form of cefotaxime. Hydrolysis of cefotaxime by 192 
ESBL producers was characterized by disappearance of the non-hydrolyzed form of 193 
cefotaxime. ESBL, extended-spectrum β-lactamase. 194 
 195 
Figure 2. Distributions of normalized logRQ values for strains tested using the 196 
cefotaxime hydrolysis assay. Normalized logRQ values >0.4 or <0.2 indicate positive or 197 
negative results, respectively. Values between 0.2 and 0.4 were considered 198 
indeterminate. ESBL, extended-spectrum β-lactamase; MIC, minimum inhibitory 199 
concentration. 200 
 
Table 1. Characteristics of Enterobacteriaceae evaluated in this study. 
Bacterial species ESBL genotype ESBL production MIC for cefotaxime (μg/mL) n 
Escherichia coli CTX-M group 1 Positive >32 2 
 CTX-M group 9 Positive >32 12 
 CTX-M group 1, TEM Positive >32 1 
 CTX-M group 9, TEM Positive >32 7 
 Negative Negative ≤1 20 
Klebsiella pneumoniae CTX-M group 9 Positive >32 1 
 SHV Positive >32 1 
 SHV Positive ≤1 3 
 CTX-M group 1, SHV Positive >32 6 
 CTM-M group 2, SHV Positive >32 3 
 CTM-M group 9, TEM Positive >32 2 
 TEM, SHV Positive ≤1 1 
 CTX-M group 1, TEM Positive >32 1 
 CTX-M group 1, TEM, SHV Positive >32 2 
 Negative Negative ≤1 18 
Total    80 
ESBL, extended-spectrum β-lactamase; MIC, minimum inhibitory concentration. 
Figure 1. Representative spectra of the cefotaxime hydrolysis assay analyzed using the MBT STAR-BL 
assay. Non-ESBL producers exhibited peaks at 456, 478, and 396 m/z, corresponding to the non-
hydrolyzed form of cefotaxime. Hydrolysis of cefotaxime by ESBL producers was characterized by 
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Figure 2. Distributions of normalized logRQ values for strains tested using the cefotaxime 
hydrolysis assay. Normalized logRQ values >0.4 or <0.2 indicate positive or negative results, 
respectively. Values between 0.2 and 0.4 were considered indeterminate. ESBL, extended-
spectrum β-lactamase; MIC, minimum inhibitory concentration.
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